Effect of cyclodextrins on the complexation and transdermal delivery of bupranolol through rat skin

被引:50
作者
Babu, RJ [1 ]
Pandit, JK
机构
[1] Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Tallahassee, FL 32307 USA
[2] Banaras Hindu Univ, Inst Technol, Dept Pharmaceut, Varanasi 221005, Uttar Pradesh, India
关键词
bupranolol; hydroxypropyl-beta-cyclodextrin; methylated-beta-cyclodextrin; transdermal; permeation; penetration enhancer;
D O I
10.1016/j.ijpharm.2003.11.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Bupranolol (BPL) is a potent beta-blocking agent, the extensive first-pass metabolism (>90%) and rapid elimination half-life (1.5-2.0 h) of this drug make it well suited to be developed as a transdermal delivery system (TDS). Hydroxypropyl betaCD (HPbetaCD) and partially methylated PCD (PMbetaCD) were used as penetration enhancers for BPL. The formation of inclusion complex of BPL with these cyclodextrins (CDs) was characterized in solution and solid states by phase solubility, X-ray diffractometry and differential scanning calorimetry (DSC) analyses. The effect of CDs on the permeation enhancement of BPL through rat skin was studied using side-by-side diffusion cells and pH 7.4 phosphate-buffered saline (PBS). CDs were employed at different concentrations with 0.4% (w/v) BPL as well as with excess quantity of BPL (1.0%, w/v) that CDs could not complex all the BPL and the drug was in the form of an aqueous suspension. The permeation of BPL from its aqueous suspension (0.4%, w/v) significantly increased when CDs were used at low concentrations (up to 2 and 5%, w/v concentration for HPbetaCD and PMbetaCD, respectively) (P < 0.01). At higher CD concentrations, the permeation of BPL decreased; and both CDs at 10% (w/w), showed similar flux values to that of control (no enhancer, P > 0.05). The permeation of BPL from its 1.0% (w/v) aqueous suspension increased with increase in concentration of CD up to 10% (w/v) for HPbetaCD and PMbetaCD. At 10% (w/v) concentration of HPbetaCD and PMbetaCD, the flux of BPL from its 1.0% aqueous suspension increased 3.8- and 4.6-fold (P < 0.01 and P < 0.001, respectively). The permeation data of skin pretreatment with CDs indicate that HPbetaCD had no effect on the skin, whereas PMbetaCD significantly reduced the skin barrier for BPL, as shown by 1.7-fold increase in the flux by PMbetaCD pretreatment (P < 0.001). Overall, both HPbetaCD and PMbetaCD were found to be suitable for improving the solubility and penetration enhancement of BPL. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:155 / 165
页数:11
相关论文
共 29 条
[1]  
AMDIDOUCHE D, 1989, INT J PHARM, V54, P175
[2]  
BABU RJ, 1995, STP PHARMA SCI, V5, P196
[3]   Influence of hydroxypropyl-β-cyclodextrin on the transdermal permeation and skin accumulation of oxybenzone [J].
Felton, LA ;
Wiley, CJ ;
Godwin, DA .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2002, 28 (09) :1117-1124
[4]   PHYSICOCHEMICAL ASPECTS OF THE TRANSDERMAL DELIVERY OF BUPRANOLOL [J].
GREEN, PG ;
HADGRAFT, J ;
WOLFF, M .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1989, 55 (2-3) :265-269
[5]  
Higuchi T., 1965, Interscience, New York, V4, P117
[6]   Study of the complexation behavior of tenoxicam with cyclodextrins in solution: Improved solubility and percutaneous permeability [J].
Larrucea, E ;
Arellano, A ;
Santoyo, S ;
Ygartua, P .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2002, 28 (03) :245-252
[7]   INVITRO PENETRATION OF SOME BETA-ADRENORECEPTOR BLOCKING-DRUGS THROUGH PORCINE BUCCAL MUCOSA [J].
LEBRUN, PPH ;
FOX, PLA ;
DEVRIES, ME ;
BODDE, HE .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1989, 49 (02) :141-145
[8]   Effects of beta-cyclodextrins on skin: Implications for the transdermal delivery of piribedil and a novel cognition enhancing-drug, S-9977 [J].
Legendre, JY ;
Rault, I ;
Petit, A ;
Luijten, W ;
Demuynck, I ;
Horvath, S ;
Ginot, YM ;
Cuine, A .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 3 (06) :311-322
[9]  
LOFTSSON T, 1991, EUR J PHARM BIOPHARM, V37, P30
[10]   Cyclodextrins in topical drug formulations: theory and practice [J].
Loftsson, T ;
Masson, M .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 225 (1-2) :15-30